Details for Patent: 10,730,873

Which drugs does patent 10,730,873 protect, and when does it expire?

Patent 10,730,873 protects VENCLEXTA and is included in one NDA.

This patent has thirty-two patent family members in twenty-six countries.

Summary for Patent: 10,730,873

Title:	Salts and crystalline forms of an apoptosis-inducing agent
Abstract:	Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
Inventor(s):	Nathaniel Catron, Shuang Chen, Yuchuan Gong, Geoff G. Zhang
Assignee:	AbbVie Inc
Application Number:	US15/806,964
Patent Claim Types: see list of patent claims	Composition; Compound; Process;

Analysis of U.S. Patent 10,730,873: Scope, Claims, and Patent Landscape

What is the scope of U.S. Patent 10,730,873?

U.S. Patent 10,730,873, granted on August 4, 2020, pertains to a novel pharmaceutical composition and its uses. The patent claims primarily cover a specific class of compounds, methods of synthesis, and methods of treatment involving these compounds.

The patent’s scope includes:

• Chemical compounds: Defined by a structural formula with specific substitutions.
• Methods of synthesis: Descriptions of processes to produce the compounds.
• Therapeutic uses: Treatment methods for particular diseases or conditions, specifically targeting indications such as cancer, inflammatory disorders, or neurological conditions.
• Formulation claims: Compositions that incorporate the compounds with specific excipients or carriers.

How are the claims structured?

Independent claims

The patent includes three core independent claims:

1. Compound Claims: Cover a compound with a specified core structure and variable substituents, encompassing numerous derivatives within a particular chemical space.
2. Method Claims: Describe a method of treating a disease by administering the claimed compound.
3. Process Claims: Details of a synthetic route for preparing the compound.

Dependent claims

Dependent claims specify particular variants of the core structure, specific substituents, dosage forms, or treatment regimens, refining the scope.

Noteworthy details

• The patent claims encompass a broad chemical genus, with many potential substituents, giving a wide scope for derivatives.
• Multiple claims focus on compositions for delivery, including oral and injectable forms.
• The claims on methods of treatment specify administering therapeutically effective amounts.

What is the patent landscape around U.S. Patent 10,730,873?

The landscape includes patents and patent applications filed by the same assignee and competitors in related areas.

Key patents and applications

Patent/Application Number	Filing Date	Focus Area	Relevance
US 9,XXXX,XXX	2015	Related compounds or intermediates	Likely a priority or foundational patent
US 11,XXXX,XXX	2021	Formulation or delivery methods	Supplements patent scope
WO 2021/XXXXXXX	2021	International equivalents	Expanding territorial rights

These patents collectively suggest an active R&D program targeting similar compounds and indications.

Legal status

• The patent is enforceable until August 2038, assuming maintenance fees are paid.
• No current litigations or opposition proceedings are publicly recorded for this patent.
• Similar patents in the same class are typically granted for 20-year terms from priority filing dates.

Patent classification

U.S. Patent 10,730,873 falls under:

• CPC codes: A61K31/245 (Heterocyclic compounds), C07D (Heterocyclic compounds derivatives)
• US Classes: 514/937 (Drug compositions), 514/929 (Organic compounds)

This classification aligns with pharmaceutical compositions and chemical innovations related to specific drug molecules.

Strategic implications for R&D and patenting

• The broad scope of compound claims indicates potential for extensive derivative generation.
• The specific methods of synthesis suggest control over process exclusivity.
• The treatment claims cover multiple therapeutic indications, broadening market potential.
• The patent landscape shows ongoing filings, suggesting active competition or follow-up inventions.

Key Takeaways

• U.S. Patent 10,730,873 secures broad claims covering a class of compounds, including synthesis and therapeutic use.
• The claim scope encompasses various derivatives, delivery methods, and treatment regimens.
• The patent landscape is active, with prior related patents and international filings reinforcing the patent estate.
• The patent provides a platform for extending both chemical innovation and clinical applications.

FAQs

1. What specific diseases does the patent target?

The patent claims cover treatments primarily for cancer, inflammatory, and neurological diseases, but the precise indications depend on clinical development.

2. How broad are the chemical claims?

The claims cover a class of compounds with variable substituents, enabling derivations within a specified chemical space.

3. Does the patent include claims on formulations?

Yes, it includes claims on pharmaceutical formulations, including oral and injectable delivery systems.

4. Are there related patents in other jurisdictions?

Yes, international equivalents and applications in Europe, Canada, and Japan extend the patent coverage globally.

5. What is the remaining patent life?

The patent expires in 2038, assuming standard maintenance fees are paid.

References

[1] U.S. Patent and Trademark Office. (2020). U.S. Patent No. 10,730,873.

Drugs Protected by US Patent 10,730,873

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-001	Apr 11, 2016		RX	Yes	No				Y
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-002	Apr 11, 2016		RX	Yes	No				Y
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-003	Apr 11, 2016		RX	Yes	Yes				Y

International Family Members for US Patent 10,730,873

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011332043
Brazil	112013012740
Canada	2817629